X
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): ER-004
Therapeutic Area: Genetic Disease Product Name: EDI200
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Pierre Fabre
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration December 14, 2020
Details:
The Pierre Fabre group will be granted exclusive worldwide rights for the development, manufacturing and commercialization of ER-004. EspeRare and the Pierre Fabre Group will pool their respective expertise together in order to co-develop ER-004.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): PHA-022121
Therapeutic Area: Genetic Disease Product Name: PHVS416
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Viking Global Investors
Deal Size: $80.0 million Upfront Cash: Undisclosed
Deal Type: Series C Financing November 18, 2020
Details:
The proceeds from the Series C financing will fund the clinical advancement of Pharvaris’ pipeline of novel oral bradykinin-B2-receptor antagonists for the treatment of HAE, including both on-demand treatment and prophylactic prevention.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): PHA121
Therapeutic Area: Genetic Disease Product Name: PHVS416
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 13, 2020
Details:
The PK/PD profile suggests that rapid onset of action and prolonged efficacy with a single dose of PHA121 in the treatment of acute HAE attacks. Pharvaris is preparing to start an on-demand study of PHVS416, a soft capsule formulation of PHA121, for HAE attacks in 2021.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
